46
Participants
Start Date
June 12, 2017
Primary Completion Date
February 18, 2021
Study Completion Date
December 22, 2021
RAD001
"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
Placebo
"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
Cleveland Clinic, Cleveland
Stanford University, Palo Alto
Boston Children's Hospital, Boston
Collaborators (2)
National Institutes of Health (NIH)
NIH
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Office of Rare Diseases (ORD)
NIH
National Center for Advancing Translational Sciences (NCATS)
NIH
Novartis Pharmaceuticals
INDUSTRY
PTEN Research
UNKNOWN
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Boston Children's Hospital
OTHER